Press release April 23, 2019 Umeå life science company Lipum will participate in one of the world's largest congresses for rheumatic diseases this June. “The elite of our industry gathers at this congress once a year and competition is incredibly intense. It’s important to be seen there”, says Einar Pontén, CEO of Lipum. This year [...]
Lipum is attending two significant events in Vienna next week. At the RESI Europe and the BIO-Europe Spring meetings we will meet with key decision makers from the pharma and venture capital segments. These events take place March 25-27 and provides an opportunity to meet, please contact us and learn more about our unique approach [...]
Press release march 19 2019 Abzena, the global biologics gene to GMP partner research organization, announced it has signed an agreement to support an integrated CMC program with Lipum, a company developing treatments for chronic inflammatory diseases. Abzena will support Lipum’s anti-BSSL antibody IND program to help develop a novel therapeutic option for autoimmune inflammatory [...]
Pressrelease 3 juni, 2019 Ladda ned pressrelase: Investerare satsar 25 MSEK på nytt läkemedel (pdf) » Umeåföretaget Lipum utvecklar ett biologiskt läkemedel för behandling av kroniska inflammationer. Tidigare pre-kliniska studier har visat mycket goda resultat och potential att ge en bättre behandling av till exempel ledgångsreumatism. ”Konkurrensen i branschen är hård så när vi nyligen [...]
On 6-7 March, Lipum attends a pitching event for Deep Tech companies in Stockholm hosted by The European Innovation Council (EIC) pilot and Nasdaq. The event is exclusively organised for EIC pilot- funded companies with the opportunity to pitch their business to top European investors and connect with Nasdaq representatives and partners. The 15 attending [...]
Tomorrow, Lipum will close a share issue raising SEK 25 million in addition to support from Horizon 2020 of SEK 23 million grant. The capital will finance the preclinical work and the development of a production method up to the start of toxicology studies next year. See the full interview (in swedish) from BioStock [...]
At this event we will present the progress of our unique and EU Horizon 2020 supported approach for treatment of chronic inflammatory diseases. In addition, it will also be an opportunity to learn more about Orexo with a market cap of SEK 2.6 billion. Surprisingly, the brilliant Swedish pop group Torsson will be represented. In [...]
Thursday 7th February we will spend with potential investors and partners together with 14 participating companies from Umeå. It's the annual Biotech Umeå Investment Day 2019. We are looking forward to this event since we are at the stage of finding investors for our exciting progress towards a new drug against chronic inflammatory diseases. We [...]
According to Johnson & Johnson there are still tons of opportunity in the immunology market, even though it´s crowded. Jennifer Taubert, executive vice president and worldwide pharma chairman recently said at the J.P. Morgan Healthcare Conference: “We do look at immunology as being very, very attractive, and in certain areas, there’s so much unmet medical [...]
"Sweden is number eight on the list of European countries that receive the most money" says Johan Lindberg at Vinnova, who helps Swedish companies to apply for EU grants. So far, Sweden has received SEK 10 billion through the EU Innovation Fund Horizon 2020, of which 25 million was allocated to Lipum for the development [...]